← back to search

Gavin Hui

Indiana University Health · US
Area of research
Oncology · Surgery
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Inflammatory Bowel Disease, and Acute Myeloid Leukemia Research.
h-index
10
citations
459
works
61
NIH funding
primary concept
email

Recent publications

Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: <scp>GLP</scp> ‐1 Receptor Agonists Versus <scp>FDA</scp> ‐Approved <scp>AUD</scp> Medications
Alimentary Pharmacology & Therapeutics 2026cited by 4position: middledoi
P-2074. Prevalence and health care utilization outcomes of Z codes in patients with HIV, Tuberculosis Disease, Hepatitis B Virus Infection, and Hepatitis C virus Infection
Open Forum Infectious Diseases 2026cited by 0position: middledoi
P-910. Systemic Antibiotic Use Among the Last 30 Days of Life in Patients with Metastatic Cancer
Open Forum Infectious Diseases 2026cited by 0position: middledoi
Answering real-world clinical questions using large language model, retrieval-augmented generation, and agentic systems
Digital Health 2025cited by 26position: middledoi
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Journal for ImmunoTherapy of Cancer 2025cited by 5position: middledoi
D33. Oncoplastic Breast Surgery: Optimizing Resection Margins in Addition to Aesthetic Outcomes
Plastic & Reconstructive Surgery Global Open 2025cited by 0position: middledoi
Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?
Diabetes Spectrum 2025cited by 0position: middledoi
Estrogen exposure from modern contraceptives and vascular risk in women with migraine: A nationwide electronic medical record database study
Cephalalgia 2025cited by 0position: middledoi
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor
Clinical Genitourinary Cancer 2024cited by 9position: middledoi
Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies
Multiple Sclerosis and Related Disorders 2024cited by 1position: middledoi
Statin use is associated with reduction in risk of <i>de novo</i> primary sclerosing cholangitis among patients with inflammatory bowel disease: A National Database Study
medRxiv 2024cited by 0position: middledoi
The Potential Revolution of Cancer Treatment with CRISPR Technology
Cancers 2023cited by 62position: middledoi
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
JNCI Journal of the National Cancer Institute 2023cited by 54position: middledoi
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
Journal of Clinical Oncology 2023cited by 3position: middledoi
Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020.
Journal of Clinical Oncology 2021cited by 0position: middledoi
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era
Clinical Genitourinary Cancer 2017cited by 52position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Saurabh Gombar · Palo Alto University4 papers (2024–2026)C. William Pike · Georgetown University4 papers (2024–2025)Michael L. Jackson · Kaiser Permanente Washington Health Research Institute3 papers (2024–2025)Alexandra Drakaki · University of Colorado Denver2 papers (2017–2023)Allan J. Pantuck · Urologic Research Institute2 papers (2017–2023)Daisuke Furukawa · Palo Alto University2 papers (2026–2026)Paul Y. Kwo · Palo Alto University2 papers (2025–2026)Sun H. Kim · Horizon Therapeutics (United States)1 papers (2025–2025)Yuliya Zektser · University of California, Los Angeles1 papers (2023–2023)Heather A. Wakelee · Stanford University1 papers (2021–2021)Pooja Yesantharao · Palo Alto University1 papers (2025–2025)Dimitrios Stefanoudakis · National and Kapodistrian University of Athens1 papers (2023–2023)Andrea B. Apolo · National Institutes of Health1 papers (2023–2023)Mohammed F. Shaheen · Palo Alto University1 papers (2025–2025)Nikhita Kathuria‐Prakash · APLA Health1 papers (2023–2023)Gregory R. Pond · Université Claude Bernard Lyon 11 papers (2023–2023)Sandy Liu · Diamond Materials (United States)1 papers (2017–2017)Marcie Levine · Palo Alto University1 papers (2025–2025)Karim Chamie · UCLA Medical Center1 papers (2017–2017)Guru Sonpavde · AdventHealth Orlando1 papers (2023–2023)